|1.||Isaacs, John T: 8 articles (09/2014 - 12/2006)|
|2.||Leanderson, Tomas: 7 articles (02/2015 - 12/2006)|
|3.||Olsson, Anders: 7 articles (02/2015 - 12/2006)|
|4.||Pili, Roberto: 6 articles (02/2015 - 12/2006)|
|5.||Dalrymple, Susan L: 5 articles (09/2014 - 12/2006)|
|6.||Björk, Anders: 4 articles (02/2013 - 12/2006)|
|7.||Carducci, Michael A: 3 articles (11/2014 - 10/2011)|
|8.||Shen, Li: 2 articles (02/2015 - 01/2014)|
|9.||Sundstedt, Anette: 2 articles (02/2015 - 01/2015)|
|10.||Törngren, Marie: 2 articles (01/2015 - 06/2012)|
|1.||Prostatic Neoplasms (Prostate Cancer)
09/30/2014 - "Clinical trials document that as low as 0.5-1mg tasquinimod/day is therapeutic against castrate resistant metastatic prostate cancer. "
01/01/2014 - "Tasquinimod is an orally available agent that has shown efficacy and favorable safety profile as deduced by the results of Phase I and II clinical trials of this drug in prostate cancer. "
04/01/2013 - "A confirmatory Phase III trial of tasquinimod in prostate cancer is underway. "
10/20/2011 - "Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer."
05/01/2015 - "[Tasquinimod: How to act on microenvironment in metastatic prostate cancer]."
05/01/2012 - "At clinically relevant drug levels, tasquinimod significantly (P < 0.05) enhances anti-cancer efficacy of fractionated radiation with optimal timing for initiating daily tasquinimod treatment being after completion of the fractionated radiation. "
06/01/2012 - "In conclusion, this study and clinical data show that tasquinimod interferes with the metastatic process, presumably by inhibition of tumor establishment. "
02/01/2015 - "A target of tasquinimod is the inflammatory protein S100A9, which has been demonstrated to affect the accumulation and function of tumor-suppressive myeloid cells. "
01/01/2015 - "Our data show that tasquinimod affects tumor infiltrating myeloid cells early after exposure, leading to a change in phenotype from pro-angiogenic and immunosuppressive M2-like TAMs to pro-inflammatory M1-like macrophages. "
01/01/2015 - "Here, we show that tasquinimod treatment induces an anti-tumor effect which is subsequent to a reduction in tumor infiltrating CD206(+) M2 macrophages and a simultaneous increase in M1 macrophages expressing MHC class II and CD86. "
|3.||Neoplasm Metastasis (Metastasis)
12/15/2013 - "The survival observed in this trial of men with minimally symptomatic mCRPC suggests that the prolongation in PFS with tasquinimod may lead to a survival advantage in this setting, particularly among men with skeletal metastases, and has a favorable risk:benefit ratio."
01/01/2014 - "Tasquinimod inhibits the growth and metastasis of tumour cells in vitro and in vivo. "
12/15/2013 - "With 111 mortality events, median OS was 33.4 months for tasquinimod versus 30.4 months for placebo overall, and 34.2 versus 27.1 months in men with bone metastases (n = 136), respectively. "
01/01/2015 - "These changes are consistent with the effects of tasquinimod seen on tumor vascularization, immune suppression and metastasis giving further insights to the anti-tumor mechanism of action of tasquinimod."
01/01/2015 - "The switch in TAM polarization by tasquinimod was confirmed in the 4T1 breast cancer model where tasquinimod also reduce lung metastasis development. "
|4.||Vascular Tissue Neoplasms
05/01/2012 - "Based upon cell culture studies and tumor tissue oxygenation (i.e., pO(2)), tumor vascular volume, and tumor blood vessel density measurements, the mechanism for such enhancement and optimal timing involves tasquinimod's ability to prevent the angiogenic rebound induced by fractionated radiation."
05/15/2007 - "These studies documented that daily oral treatment with tasquinimod consistently, statistically (P < 0.05) inhibited the tumor growth of each of the xenografts in a dose-dependent manner via an anti-angiogenic response as monitored by a significant (P < 0.05) decrease in the tumor blood vessel density. "
10/20/2009 - "Long-term continuous oral administration of tasquinimod seems to be safe, and the overall efficacy results indicate that tasquinimod might delay disease progression."
12/15/2013 - "Tasquinimod (Active Biotech) is an oral immunomodulatory, anti-angiogenic, and anti-metastatic agent that delayed metastatic disease progression in a randomized placebo-controlled phase II trial in men with metastatic castration-resistant prostate cancer (mCRPC). "
09/01/2013 - "Tasquinimod, an oral quinolone-3-carboxamide with anti-tumor activity in preclinical models of prostate cancer, has been tested in patients with minimally symptomatic castration-resistant prostate cancer (CRPC), showing promising inhibitory effects on the occurrence of metastasis and delayed disease progression. "
06/01/2012 - "Tasquinimod (ABR-215050) is an orally active quinoline-3-carboxamide analog that has completed phase II clinical trial in patients with castration resistant prostate cancer, showing promising inhibiting effects on the occurrence of metastasis and delayed disease progression. "
|3.||Cytochrome P-450 CYP3A
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)